Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

RuiYi Selects CMC Biologics to Develop Cell Line for mAb

publication date: May 14, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
RuiYi Inc., a San Diego-Shanghai pre-clinical stage pharma, has enlisted CMC Biologics to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics, which is located in Seattle and Copenhagen, will use its proprietary CHEF1® high-productivity expression plasmid for the cell line. RuiYi in-licensed global rights to RYI-008 last October from ArGEN-X, a Dutch company. The molecule is being developed as a treatment for cancer and inflammatory diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners